Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC
Introduction - Data of first-line ramucirumab plus pembrolizumab treatment of programmed death-ligand 1 (PD-L1)-positive NSCLC (cohort E) are reported (NCT02443324). - Methods - In this multicenter, open-label phase 1a/b trial, patients received ramucirumab 10 mg/kg and pembrolizumab 200 mg every 21...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2021
|
| In: |
Journal of thoracic oncology
Year: 2021, Jahrgang: 16, Heft: 2, Pages: 289-298 |
| ISSN: | 1556-1380 |
| DOI: | 10.1016/j.jtho.2020.10.004 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtho.2020.10.004 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1556086420308091 
|
| Verfasserangaben: | Roy S. Herbst, MD, PhD, Hendrik Tobias Arkenau, MD, Johanna Bendell, MD, Edward Arrowsmith, MD, Martin Wermke, MD, Andres Soriano, MD, Nicolas Penel, MD, Rafael Santana-Davila, MD, Helge Bischoff, MD, Ian Chau, MD, Gu Mi, PhD, Hong Wang, PhD, Erik Rasmussen, PhD, David Ferry, MD, Bo H. Chao, MD, Luis Paz-Ares, MD |
| Zusammenfassung: | Introduction - Data of first-line ramucirumab plus pembrolizumab treatment of programmed death-ligand 1 (PD-L1)-positive NSCLC (cohort E) are reported (NCT02443324). - Methods - In this multicenter, open-label phase 1a/b trial, patients received ramucirumab 10 mg/kg and pembrolizumab 200 mg every 21 days for up to 35 cycles. PD-L1 positivity was defined as tumor proportion score (TPS) greater than or equal to 1%. Exploratory NanoString biomarker analyses included three T-cell signatures (T-cell-inflamed, Gajewski, and effector T cells) and CD274 gene expression. - Results - Cohort E included 26 patients. Treatment-related adverse events of any grade occurred in 22 patients (84.6%). Treatment-related adverse events of grade greater than or equal to 3 were reported in 11 patients (42.3%); the most frequent was hypertension (n = 4, 15.4%). Objective response rate was 42.3% in the treated population and 56.3% and 22.2% for patients with high (TPS ≥ 50%) and lower levels (TPS 1%-49%) of PD-L1 expression, respectively. Median progression-free survival (PFS) in the treated population was 9.3 months, and 12-month and 18-month PFS rates were 45% each. Median PFS was not reached in patients with PD-L1 TPS greater than or equal to 50% and was 4.2 months in patients with PD-L1 TPS 1% to 49%. Median overall survival was not reached in the treated population, and 12-month and 18-month overall survival rates were 73% and 64%, respectively. Biomarker data suggested a positive association among clinical response, three T-cell signatures, CD274 gene expression, and PD-L1 immunohistochemistry. - Conclusions - First-line therapy with ramucirumab plus pembrolizumab has a manageable safety profile in patients with NSCLC, and the efficacy signal seems to be strongest in tumors with high PD-L1 expression. |
|---|---|
| Beschreibung: | Available online 15 October 2020 Gesehen am 12.05.2021 |
| Beschreibung: | Online Resource |
| ISSN: | 1556-1380 |
| DOI: | 10.1016/j.jtho.2020.10.004 |